Unveiling the Dark Side of Enzyme Inhibition: A Surprising Cancer Risk
Blocking a key cellular enzyme once thought to protect against fatty liver disease may actually increase the risk of chronic liver damage and cancer as we age. This groundbreaking discovery by scientists from Adelaide University challenges the growing interest in Caspase-2 inhibitors as a therapeutic strategy and highlights the need for caution when targeting this pathway.
In a major new study published in Science Advances, researchers found that loss of the enzyme Caspase-2 drives abnormal growth in liver cells, triggering inflammation, fibrosis, and a significantly higher risk of liver cancer. The findings overturn assumptions that inhibiting Caspase-2 is universally beneficial, and instead reveal its essential role in removing damaged and abnormal liver cells as we age.
Caspase-2 plays a critical role in maintaining the genetic stability of liver cells while also having an independent role in controlling fat levels in the liver, according to lead researcher Dr Loretta Dorstyn from the Centre for Cancer Biology. Without the enzyme, abnormally high levels of polyploidy in the liver can be damaging, leading to chronic liver inflammation and characteristics of hepatitis-like liver disease, including scarring, oxidative damage, and a type of cell death linked to inflammation.
Using genetically modified mouse models, the researchers found that in mice lacking the enzyme, or had a version of it that no longer worked, liver cells were abnormally large with excessive amounts of genetic and cellular damage. Over time, these mice developed chronic liver inflammation and characteristics of hepatitis-like liver disease, including scarring, oxidative damage, and a type of cell death linked to inflammation. As the animals aged, they were much more likely to develop liver cancer.
The study has important implications for drug development, as there has been significant interest in targeting Caspase-2 to treat metabolic liver disease and reduce liver cancer risk. However, the research shows that this approach could have serious unintended consequences later in life, increasing susceptibility to chronic liver inflammation, fibrosis, and cancer.
'While inhibiting this enzyme can be protective in young animals or may help prevent fatty liver disease in the short term, our study shows that its long-term loss is clearly detrimental,' said Dr Dorstyn. 'Our study demonstrates that Caspase-2 is essential for removing damaged and abnormal liver cells as we age. Without it, these cells accumulate, and can become cancerous, while also creating an environment that predisposes the liver to cancer.'
The study also raises thought-provoking questions for the audience. What are your thoughts on the potential risks and benefits of targeting Caspase-2 for therapeutic purposes? Do you think more research is needed to fully understand the implications of enzyme inhibition on liver health? Share your thoughts and opinions in the comments below!
